Annexin Pharmaceuticals

15.10 SEK

-0.98 %

Less than 1K followers

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-0.98 %
+20.32 %
+5.59 %
-23.74 %
-40.55 %
-52.81 %
-74.53 %
-85.11 %
-95.28 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Read more
Market cap
106.59M SEK
Turnover
22.88K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16/7
2026

Interim report Q2'26

22/10
2026

Interim report Q3'26

11/2
2027

Annual report '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.